The American Diabetes Association's 2026 Scientific Sessions — the world's largest diabetes research conference — concluded this weekend in New Orleans, and among its numerous presentations was a finding that deserves far wider attention than it has received outside the specialized diabetes medicine community.
Medscape Medical News on June 6, 2026 reported on results for petrelintide — a novel dual amylin-calcitonin receptor agonist being developed by Zealand Pharma — showing improved tolerability compared to existing GLP-1 receptor agonists while delivering clinically meaningful weight loss and glycemic improvement. The ADA 2026 presentation confirms petrelintide as the leading candidate in an emerging class of drugs that may address the approximately 30–40% of patients who discontinue GLP-1 therapy due to intolerable gastrointestinal side effects — nausea, vomiting, and the loss of appetite that can cross from therapeutic to medically concerning in some patient populations.
